Personalis Unveils Therapy Resistance Tracking in ctDNA Assay
Event summary
- Personalis will present data at the AACR Annual Meeting (April 17-22, 2026) focused on its NeXT Personal ultrasensitive ctDNA assay.
- A key feature highlighted is the 'Real-Time Variant Tracker,' a new MRD test option designed to longitudinally track therapy resistance mutations.
- The AACR presentations include an oral podium presentation on colorectal cancer data and three poster presentations.
- One poster focuses on analytical validation and real-world data for the Real-Time Variant Tracker, while another demonstrates detection levels below 100 ppm and 10 ppm across various cancers.
The big picture
Personalis's focus on ultrasensitive ctDNA analysis and therapy resistance tracking reflects a broader trend towards personalized oncology and earlier cancer detection. The introduction of the Real-Time Variant Tracker positions Personalis to capture a larger share of the growing MRD testing market, which is increasingly important for guiding treatment decisions and monitoring disease recurrence. However, the company's success hinges on demonstrating clinical utility and securing favorable reimbursement policies.
What we're watching
- Clinical Adoption
- The pace at which oncologists integrate the Real-Time Variant Tracker into clinical workflows will determine its commercial success and impact on patient management.
- Competitive Landscape
- How competitors respond to Personalis’s introduction of Real-Time Variant Tracker, particularly in terms of developing similar capabilities, will shape the future of MRD testing.
- Reimbursement
- Whether payers will reimburse for the Real-Time Variant Tracker, given its complexity and potential to influence treatment decisions, will be crucial for Personalis’s revenue growth.
Related topics